Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study identified several gonadal hormone drugs, including toremifene citrate, tamoxifen citrate, and clomiphene citrate, that effectively inhibited filovirus entry in a pseudovirus model.

This article discusses the potential for combining PROTACs with other therapeutic modalities in drug discovery and reports no clinical results.

This study found that liarozole is more effective than cyproterone acetate for improving PSA response and survival in metastatic prostate cancer after first-line endocrine therapy, while maintaining quality of life.

This study used molecular docking simulations to identify Adapalene, Diosmin, and Azelastine as promising drugs for repurposing against onchocerciasis by targeting proteins in the parasite and its endosymbiont; further research is needed to confirm their efficacy.

This study found that four new progesterone derivatives reduced prostate weight in gonadectomized hamsters, suggesting potent in vivo antiandrogenic effects similar to finasteride.

This study observed that new trienone compounds consistently showed higher 5alpha-reductase inhibitory activity compared to corresponding dienones across various biological models.

This study found that a new hybrid compound designed from finasteride and epristeride was a potent inhibitor of 5α-reductase with a mechanism similar to finasteride.

Two new compounds can block androgen receptor activity in different ways and may lead to new treatments for androgen-related diseases.

This review highlights the potential of peptide-based PROTACs (pPROTACs) in expanding the target range of protein degraders beyond small-molecule limitations, particularly for undruggable proteins, by utilizing advances in design, conjugation, and bioPROTAC technology.

This study reported that while no synthesized compounds surpassed finasteride in 5α-reductase inhibitory activity, certain 4-azasteroid-2-oximes exhibited notable inhibition.

This study found that olorofim demonstrated potent in vitro and in vivo antifungal activity against dermatophytes, resolving skin lesions in a guinea pig model similar to clotrimazole, suggesting it may be a promising treatment for dermatophytosis.

This study found that aliphatic ester moieties in 16-formyl-17-methoxy dehydroepiandrosterone derivatives increased their potency as 5α-reductase type 2 inhibitors in vitro compared to finasteride.

This review discusses targeting host cell proteases as a novel approach to inhibit SARS-CoV-2 infection, highlighting transcriptional modulation and enzymatic inhibition as promising therapeutic strategies, but it reports no new clinical findings.

This article reviews different generations of synthetic retinoids for dermatological use, discussing their efficacy and significant side effects, but reports no new clinical results.

In this study, 13-cis-5S*,8S*-epidioxy-5,8-dihydroretinoic acid was found to be significantly more cytotoxic to cancer cell lines than other retinoic acid analogs evaluated.

This study found that cepharanthine significantly inhibits EqHV-8 infection in vitro and improves lung tissue pathology in infected mice by reducing oxidative stress through specific signaling pathways, suggesting its potential as a treatment for equid herpesvirus type 8.

This study used molecular docking simulations to identify Adapalene, Diosmin, and Azelastine as promising drugs for repurposing against Onchocerciasis by targeting Onchocerca volvulus and its endosymbiont; further research is suggested to confirm their efficacy.

This study reported that newly synthesized progesterone derivatives significantly reduced prostate weight in testosterone-treated hamsters, with 5alpha-reductase inhibitory activity dependent on the size of the substituent at C-17.

This study reports that VP-16-213 (etoposide) shows significant therapeutic activity in several cancers including small cell bronchogenic carcinoma and certain leukemias, with hematologic toxicity being the primary side effect.

This review highlights the potential of PROTACs to transform cancer treatment by selectively degrading oncogenic proteins, overcoming drug resistance, and reducing toxicity; it also discusses challenges in optimizing these therapies for personalized applications.

This review covers the potential of repurposing existing drugs for treating COVID-19 and updates on virus- and host-targeting drug candidates, reporting no new experimental results.

This study found that epitestosterone acts as a weak antiandrogen by inhibiting receptor binding and 5α-reductase activity in animal models.

A new compound may effectively inhibit the enzyme linked to BPH and hair loss.

This study reports that five new progesterone derivatives demonstrated inhibitory activity against the 5α-reductase enzyme and binding affinity for the androgen receptor in an in vitro hamster model.

This study found that specific steroids, particularly 5 and 7b, decreased growth of prostate and seminal vesicles and bound to the androgen receptor, showing comparable pharmacological activity to finasteride.

This review discusses the role of mitochondria and evaluates methodologies for assessing mitochondrial function and toxicity, particularly in the context of HIV and antiretroviral treatments, but it reports no new empirical findings.

This review discusses the pharmacological properties and clinical applications of cyproterone acetate and similar antiandrogens, noting previous failures in local applications due to concentration limitations; it reports no new empirical results.

This study found that SARS-CoV-2 hijacks the host factor IGF2BP1 to stabilize its RNA and enhance translation, and identified Cepharanthine and Trifluoperazine as potential treatments against the virus.